Literature DB >> 24554673

Massive haemoptysis following dabigatran administration in a patient with bronchiectasis.

Manabu Hayama1, Hideki Inoue, Hiromichi Wada, Tadashi Mio.   

Abstract

We report a case of life-threatening haemoptysis after administration of dabigatran in a patient with bronchiectasis. A 72-year-old woman had received dabigatran at a dose of 110 mg twice daily for chronic atrial fibrillation. She was admitted to our hospital for cerebral infarction after a few days of self-interruption of dabigatran. After the diagnosis of cerebral infarction, administration of dabigatran was restarted. Seven days later, she suffered acute-onset massive haemoptysis and required mechanical ventilation. Dabigatran treatment was discontinued, and bronchial artery embolisation (BAE) was performed twice. The bleeding continued for 11 days, but she recovered and was discharged on day 58 after admission.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24554673      PMCID: PMC3931966          DOI: 10.1136/bcr-2013-201001

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  16 in total

Review 1.  Urgent statement on antithrombotic therapy of atrial fibrillation.

Authors:  Satoshi Ogawa; Masatsugu Hori
Journal:  Circ J       Date:  2011-11-08       Impact factor: 2.993

2.  Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): digest version.

Authors: 
Journal:  Circ J       Date:  2010-10-16       Impact factor: 2.993

Review 3.  Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant.

Authors:  Michael Ganetsky; Kavita M Babu; Steven D Salhanick; Robert S Brown; Edward W Boyer
Journal:  J Med Toxicol       Date:  2011-12

4.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association.

Authors:  A John Camm; Gregory Y H Lip; Raffaele De Caterina; Irene Savelieva; Dan Atar; Stefan H Hohnloser; Gerhard Hindricks; Paulus Kirchhof
Journal:  Eur Heart J       Date:  2012-08-24       Impact factor: 29.983

5.  Dabigatran and postmarketing reports of bleeding.

Authors:  Mary Ross Southworth; Marsha E Reichman; Ellis F Unger
Journal:  N Engl J Med       Date:  2013-03-13       Impact factor: 91.245

6.  Bronchial artery embolization : experience with 54 patients.

Authors:  Karen L Swanson; C Michael Johnson; Udaya B S Prakash; Michael A McKusick; James C Andrews; Anthony W Stanson
Journal:  Chest       Date:  2002-03       Impact factor: 9.410

7.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.

Authors:  B F Gage; A D Waterman; W Shannon; M Boechler; M W Rich; M J Radford
Journal:  JAMA       Date:  2001-06-13       Impact factor: 56.272

8.  Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score.

Authors:  Gregory Y H Lip; Lars Frison; Jonathan L Halperin; Deirdre A Lane
Journal:  J Am Coll Cardiol       Date:  2010-11-24       Impact factor: 24.094

9.  The untold story of Dabigatran etexilate: alveolar hemorrhage in an elderly patient with interstitial pulmonary fibrosis.

Authors:  Ahmad Husari; Atallah Beydoun; Amein Sheik Ammar; Joseph E Maakaron; Ali Taher
Journal:  J Thromb Thrombolysis       Date:  2013-01       Impact factor: 2.300

10.  Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose.

Authors:  Betty C Chen; Nijal R Sheth; Kobena A Dadzie; Silas W Smith; Lewis S Nelson; Robert S Hoffman; James F Winchester
Journal:  Am J Kidney Dis       Date:  2013-04-16       Impact factor: 8.860

View more
  1 in total

1.  Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study.

Authors:  Alex C Spyropoulos; Concetta Lipardi; Jianfeng Xu; Wentao Lu; Eunyoung Suh; Zhong Yuan; Bennett Levitan; Chiara Sugarmann; Yoriko De Sanctis; Theodore E Spiro; Elliot S Barnathan; Gary E Raskob
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.